

Karl-Heinz Klempnauer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4904123/publications.pdf>

Version: 2024-02-01

66
papers

3,243
citations

201385

27
h-index

155451

55
g-index

66
all docs

66
docs citations

66
times ranked

2517
citing authors

#	ARTICLE	IF	CITATIONS
1	Characterization of the MYB-inhibitory potential of the Pan-HDAC inhibitor LAQ824. <i>BBA Advances</i> , 2022, 2, 100034.	0.7	2
2	C/EBP β sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module. <i>Experimental Hematology</i> , 2022, 108, 8-15.	0.2	6
3	A synthetic covalent ligand of the C/EBP β transactivation domain inhibits acute myeloid leukemia cells. <i>Cancer Letters</i> , 2022, 530, 170-180.	3.2	8
4	Bcr-TMP, a Novel Nanomolar-Active Compound That Exhibits Both MYB- and Microtubule-Inhibitory Activity. <i>Cancers</i> , 2022, 14, 43.	1.7	9
5	Src-Family Protein Kinase Inhibitors Suppress MYB Activity in a p300-Dependent Manner. <i>Cells</i> , 2022, 11, 1162.	1.8	3
6	Natural Products with Antitumor Potential Targeting the MYB-C/EBP β -p300 Transcription Module. <i>Molecules</i> , 2022, 27, 2077.	1.7	5
7	Expression of protein kinase HIPK2 is subject to a quality control mechanism that acts during translation and requires its kinase activity to prevent degradation of nascent HIPK2. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2021, 1868, 118894.	1.9	6
8	C/EBP β is a MYB- and p300-cooperating pro-leukemogenic factor and promising drug target in acute myeloid leukemia. <i>Oncogene</i> , 2021, 40, 4746-4758.	2.6	14
9	The CDC37-HSP90 chaperone complex co-translationally degrades the nascent kinase-dead mutant of HIPK2. <i>FEBS Letters</i> , 2021, 595, 1559-1568.	1.3	4
10	Proteasome inhibitors suppress MYB oncogenic activity in a p300-dependent manner. <i>Cancer Letters</i> , 2021, 520, 132-142.	3.2	15
11	Intramolecular interaction of MYB is regulated through Ser577 phosphorylation. <i>FEBS Letters</i> , 2020, 594, 4266-4279.	1.3	6
12	PDCD4 controls the G1/S-phase transition in a telomerase-immortalized epithelial cell line and affects the expression level and translation of multiple mRNAs. <i>Scientific Reports</i> , 2020, 10, 2758.	1.6	9
13	Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells. <i>Cancer Letters</i> , 2020, 479, 61-70.	3.2	44
14	Characterization of the zinc finger proteins ZMYM2 and ZMYM4 as novel B-MYB binding proteins. <i>Scientific Reports</i> , 2020, 10, 8390.	1.6	10
15	Activation of the oncogenic transcription factor B-Myb via multisite phosphorylation and prolyl-cis/trans-isomerization. <i>Nucleic Acids Research</i> , 2019, 47, 103-121.	6.5	69
16	A novel cell-based screening assay for small-molecule MYB inhibitors identifies podophyllotoxins teniposide and etoposide as inhibitors of MYB activity. <i>Scientific Reports</i> , 2018, 8, 13159.	1.6	20
17	The natural anti-tumor compound Celastrol targets a Myb-C/EBP β -p300 transcriptional module implicated in myeloid gene expression. <i>PLoS ONE</i> , 2018, 13, e0190934.	1.1	27
18	Interplay with the Mre11-Rad50-Nbs1 complex and phosphorylation by GSK3 β implicate human B-Myb in DNA-damage signaling. <i>Scientific Reports</i> , 2017, 7, 41663.	1.6	11

#	ARTICLE	IF	CITATIONS
19	Withaferin A, a natural compound with anti-tumor activity, is a potent inhibitor of transcription factor C/EBP β . <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2017, 1864, 1349-1358.	1.9	15
20	Targeting the transcription factor Myb by small-molecule inhibitors. <i>Experimental Hematology</i> , 2017, 47, 31-35.	0.2	41
21	Small-Molecule Disruption of the Myb/p300 Cooperation Targets Acute Myeloid Leukemia Cells. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2905-2915.	1.9	47
22	Targeting acute myeloid leukemia with a small molecule inhibitor of the Myb/p300 interaction. <i>Blood</i> , 2016, 127, 1173-1182.	0.6	83
23	Helenalin Acetate, a Natural Sesquiterpene Lactone with Anti-inflammatory and Anti-cancer Activity, Disrupts the Cooperation of CCAAT Box/Enhancer-binding Protein β (C/EBP β) and Co-activator p300. <i>Journal of Biological Chemistry</i> , 2016, 291, 26098-26108.	1.6	33
24	A conserved patch of hydrophobic amino acids modulates Myb activity by mediating protein-protein interactions. <i>Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms</i> , 2016, 1859, 914-921.	0.9	1
25	Naphthol AS-E Phosphate Inhibits the Activity of the Transcription Factor Myb by Blocking the Interaction with the KIX Domain of the Coactivator p300. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 1276-1285.	1.9	60
26	Programmed cell death 4 protein (Pcd4) and homeodomain-interacting protein kinase 2 (Hipk2) antagonistically control translation of Hipk2 mRNA. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2015, 1853, 1564-1573.	1.9	13
27	Translation, Pcd4 and eIF4A. <i>Oncoscience</i> , 2015, 2, 731-732.	0.9	6
28	An evolutionarily conserved interaction of tumor suppressor protein Pcd4 with the poly(A)-binding protein contributes to translation suppression by Pcd4. <i>Nucleic Acids Research</i> , 2014, 42, 11107-11118.	6.5	21
29	Natural sesquiterpene lactones as inhibitors of Myb-dependent gene expression: Structure-activity relationships. <i>European Journal of Medicinal Chemistry</i> , 2013, 63, 313-320.	2.6	51
30	Interaction and Cooperation of the CCAAT-box Enhancer-binding Protein β (C/EBP β) with the Homeodomain-interacting Protein Kinase 2 (Hipk2). <i>Journal of Biological Chemistry</i> , 2013, 288, 22257-22269.	1.6	18
31	B-Myb promotes S-phase independently of its sequence-specific DNA binding activity and interacts with polymerase delta-interacting protein 1 (Pdi1). <i>Cell Cycle</i> , 2012, 11, 4047-4058.	1.3	17
32	Interaction of the Transactivation Domain of B-Myb with the TAZ2 Domain of the Coactivator p300: Molecular Features and Properties of the Complex. <i>PLoS ONE</i> , 2012, 7, e52906.	1.1	7
33	Tumor Suppressor Protein Pcd4 Inhibits Translation of p53 mRNA. <i>Journal of Biological Chemistry</i> , 2011, 286, 42855-42862.	1.6	70
34	Structure of the Tandem MA-3 Region of Pcd4 Protein and Characterization of Its Interactions with eIF4A and eIF4G. <i>Journal of Biological Chemistry</i> , 2011, 286, 17270-17280.	1.6	29
35	Association of Tumor Suppressor Protein Pcd4 With Ribosomes Is Mediated by Protein-Protein and Protein-RNA Interactions. <i>Genes and Cancer</i> , 2010, 1, 293-301.	0.6	26
36	Myb-induced Chromatin Remodeling at a Dual Enhancer/Promoter Element Involves Non-coding RNA Transcription and Is Disrupted by Oncogenic Mutations of v-myb. <i>Journal of Biological Chemistry</i> , 2009, 284, 35314-35324.	1.6	22

#	ARTICLE	IF	CITATIONS
37	A dual activation mechanism for Myb-responsive genes in myelomonocytic cells. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 40, 219-226.	0.6	2
38	C/EBP β Induces Chromatin Opening at a Cell-Type-Specific Enhancer. <i>Molecular and Cellular Biology</i> , 2008, 28, 2102-2112.	1.1	39
39	Oncogenic point mutations in the Myb DNA-binding domain alter the DNA-binding properties of Myb at a physiological target gene. <i>Nucleic Acids Research</i> , 2007, 35, 7237-7247.	6.5	8
40	Disruption of B-myb in DT40 cells reveals novel function for B-Myb in the response to DNA-damage. <i>Oncogene</i> , 2005, 24, 7127-7134.	2.6	22
41	v-Myb Mediates Cooperation of a Cell-Specific Enhancer with the mim-1 Promoter. <i>Molecular and Cellular Biology</i> , 2005, 25, 499-511.	1.1	50
42	Regulation of the cyclin D1 and cyclin A1 promoters by B-Myb is mediated by Sp1 binding sites. <i>Gene</i> , 2005, 351, 171-180.	1.0	27
43	The cooperation of B-Myb with the coactivator p300 is orchestrated by cyclins A and D1. <i>Oncogene</i> , 2004, 23, 1392-1404.	2.6	27
44	Identification of a Myb-responsive enhancer of the chicken C/EBP β gene. <i>Oncogene</i> , 2004, 23, 5807-5814.	2.6	7
45	Transformation suppressor protein Pcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. <i>Oncogene</i> , 2004, 23, 7484-7493.	2.6	133
46	Recruitment of p300 by C/EBP β triggers phosphorylation of p300 and modulates coactivator activity. <i>EMBO Journal</i> , 2003, 22, 882-892.	3.5	105
47	Transactivation mediated by B-Myb is dependent on TAFII250. <i>Oncogene</i> , 2003, 22, 2932-2941.	2.6	11
48	The transformation suppressor protein Pcd4 shuttles between nucleus and cytoplasm and binds RNA. <i>Oncogene</i> , 2003, 22, 4905-4910.	2.6	86
49	Analysis of DNase I-Hypersensitive Sites in the Chromatin of the Chicken C/EBP β Gene Reveals Multiplex-Regulatory Elements. <i>DNA and Cell Biology</i> , 2003, 22, 201-208.	0.9	3
50	Targeted disruption of c-myb in the chicken pre B-cell line DT40. <i>Oncogene</i> , 2002, 21, 3076-3081.	2.6	21
51	Identification and characterization of the Myb-inducible promoter of the chicken adenosine receptor 2B gene. <i>Oncogene</i> , 2002, 21, 4663-4673.	2.6	9
52	The chicken Pcd4 gene is regulated by v-Myb. <i>Oncogene</i> , 2001, 20, 231-239.	2.6	49
53	Identification of the myb-inducible promoter of the chicken Pcd4 gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 2001, 1520, 99-104.	2.4	18
54	Identification of cyclin A/Cdk2 phosphorylation sites in B-Myb. <i>FEBS Journal</i> , 2001, 260, 384-391.	0.2	37

#	ARTICLE	IF	CITATIONS
55	Regulation of B-Myb activity by cyclin D1. <i>Oncogene</i> , 2000, 19, 298-306.	2.6	61
56	Myb and Ets transcription factors cooperate at the myb-inducible promoter of the tom-1 gene. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999, 1446, 243-252.	2.4	13
57	The v-Myb oncoprotein activates C/EBP β expression by stimulating an autoregulatory loop at the C/EBP β promoter. <i>Biochimica Et Biophysica Acta Gene Regulatory Mechanisms</i> , 1999, 1447, 175-184.	2.4	25
58	Solution Structure of the B-Myb DNA-Binding Domain: A Possible Role for Conformational Instability of the Protein in DNA Binding and Control of Gene Expression. <i>Biochemistry</i> , 1998, 37, 9619-9629.	1.2	24
59	B-Myb and cyclin D1 mediate heat shock element dependent activation of the human HSP70 promoter. <i>Oncogene</i> , 1997, 14, 1223-1229.	2.6	30
60	The chicken adenosine receptor 2B gene is regulated by v-myb. <i>Oncogene</i> , 1997, 15, 213-221.	2.6	29
61	Phosphorylation and activation of B-Myb by cyclin A-Cdk2. <i>Current Biology</i> , 1997, 7, 253-260.	1.8	103
62	Structure of the B-Myb DNA-binding Domain in Solution and Evidence for Multiple Conformations in the Region of Repeat-2 Involved in DNA Binding. Implications for Sequence-Specific DNA Binding by Myb Proteins. <i>FEBS Journal</i> , 1996, 235, 721-735.	0.2	28
63	Characterization of the v-mybDNA binding domain. <i>Nucleic Acids Research</i> , 1990, 18, 1703-1710.	6.5	45
64	Viral myb oncogene encodes a sequence-specific DNA-binding activity. <i>Nature</i> , 1988, 335, 835-837.	13.7	606
65	The product of the retroviral transforming gene v-myb is a truncated version of the protein encoded by the cellular oncogene c-myb. <i>Cell</i> , 1983, 33, 345-355.	13.5	229
66	Nucleotide sequence of the retroviral leukemia gene v-myb and its cellular progenitor c-myb: The architecture of a transduced oncogene. <i>Cell</i> , 1982, 31, 453-463.	13.5	568